Bradley Edgington, DO
Pulmonary Disease · Tulsa, OKNPI 1366588295
Payments from drug & device makers
What this record shows
This record is dominated by education: $9,077 of the $11,831 with a category attached, or 76.7%. Intuitive Surgical accounts for 83.2% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2022 at $9,847 and has fallen 92.8% since, to $713 in 2025.
Across 103 payments — averaging $114.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$10K
- AstraZeneca$327
- GSK$316
- Sanofi$161
- Boehringer Ingelheim$157
- Grifols USA, LLC$135
- plus $888 from 19 others
What the payments were for
- Travel & lodging$8477%
- Food & beverage$1,90816%
- Education$9,07777%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 8 | $9,847 |
| AstraZeneca | 15 | $327 |
| GSK | 20 | $316 |
| Sanofi | 8 | $161 |
| Boehringer Ingelheim | 6 | $157 |
| Grifols USA, LLC | 5 | $135 |
| Mallinckrodt Hospital Products Inc. | 4 | $128 |
| Regeneron Healthcare Solutions, Inc. | 5 | $124 |
| Genentech USA, Inc. | 7 | $119 |
| Mylan Specialty L.p. | 3 | $58 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $56 |
| Viatris Specialty LLC | 2 | $54 |
| Inogen, Inc. | 3 | $43 |
| AbbVie | 2 | $41 |
| United Therapeutics Corporation | 2 | $38 |
| ANI Pharmaceuticals, Inc. | 2 | $35 |
| Insmed, Inc. | 1 | $28 |
| Philips North America LLC | 1 | $26 |
| Ambu Inc. | 1 | $24 |
| Electromed, Inc. | 1 | $23 |
| Pulmonx Corporation | 1 | $22 |
| Merck | 1 | $20 |
| Amgen | 1 | $18 |
| Vifor Pharma, Inc. | 1 | $16 |
| Verona Pharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ION$9,000
- Da Vinci Surgical System$828
How this compares
$11,831 in reported general payments places this provider in the 85th percentile of 133 pulmonary disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 192 | $136,554 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $15,478 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $10,542 |
| Incruse ElliptaUmeclidinium Bromide | 26 | $9,880 |
| Spiriva RespimatTiotropium Bromide | 18 | $9,310 |
| Arnuity ElliptaFluticasone Furoate | 19 | $6,187 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,320 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 19 | $3,709 |
| Advair DiskusFluticasone Propion/Salmeterol | 14 | $2,564 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,215 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $1,532 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 61 | $1,251 |
| Ventolin HfaAlbuterol Sulfate | 13 | $738 |
| Omeprazole | 28 | $322 |
| Pantoprazole Sodium | 11 | $102 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta, Anoro Ellipta | $316 | $173,419283 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $327 | $12,75728 claims |
| Boehringer IngelheimSpiriva Respimat | $157 | $9,31018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 133 pulmonary disease providers in Oklahoma.
Other pulmonary disease in Tulsa
- Jennifer BierachTulsa$141K
- Hassan AbouhouliTulsa$103K
- Grace KennedyTulsa$57K
- Walter BoomerTulsa$43K
- Emil SchelbarTulsa$20K
- Andrew GottehrerTulsa$16K
- Habiba HussainTulsa$10K
- Conner MoslanderTulsa$9K
- Pratyaksha SankhyanTulsa$9K
- Priyanka PathaniaTulsa$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.